Functional explanation for increased atrial natriuretic peptide in systemic sclerosis

Area of Science:

• Cardiology
• Rheumatology
• Endocrinology

Background:

• Systemic sclerosis (SScl) is associated with cardiovascular complications.
• Atrial natriuretic peptide (ANP) is a hormone involved in cardiovascular regulation.
• Elevated ANP levels can indicate cardiac stress or dysfunction.

Purpose of the Study:

• To investigate atrial natriuretic peptide (ANP) levels in patients with systemic sclerosis (SScl).
• To determine the relationship between plasma ANP and left ventricular (LV) function in SScl patients.
• To identify potential causative factors for elevated ANP in SScl.

Main Methods:

• Echocardiography and external pulse curves were used to assess LV function.
• Plasma ANP levels were measured in 30 SScl patients and 48 age- and gender-matched controls.
• Statistical analysis, including correlation and multivariate analysis, was performed.

Main Results:

• Patients with SScl exhibited significantly higher plasma ANP levels compared to controls.
• Elevated ANP was correlated with increased interventricular septal thickness, LV posterior wall thickness, and LV mass index.
• Impaired LV early filling properties and reduced atrial emptying index were observed in SScl patients, correlating with ANP levels.

Conclusions:

• Atrial natriuretic peptide (ANP) is elevated in patients with systemic sclerosis (SScl).
• Reduced left ventricular (LV) compliance, potentially due to fibrosis, may increase atrial pressure and stimulate ANP production.
• Elevated ANP in SScl is associated with LV hypertrophy and impaired diastolic function, independent of systolic dysfunction.